Intriguingly, lower dose of IL‐35 could achieve a therapeutic effect similar to what TNF‐α monoclonal antibody did in psoriasis (about a total of 50 μg hIL‐35 compared to 3.75 mg IBI303 per mouse). This evidence concerns the gene TNF and psoriasis.